1-3 of 3
Michael H Silverman, MD, FACP
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden

Animesh Pardanani, MBBS, PhD, Jason R Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Richard M Stone, M.D., Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2010) 116 (21): 459.
https://doi.org/10.1182/blood.V116.21.459.459
Published: 2010
Journal Articles

A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2 V617F Allele Burden.

Animesh D. Pardanani, MBBS, PhD, Jason R Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge Cortes, MD, Moshe Talpaz, MD, Richard Stone, MD, Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2009) 114 (22): 755.
https://doi.org/10.1182/blood.V114.22.755.755
Published: 2009
Journal Articles

A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis

Animesh D. Pardanani, MBBS, PhD, Jason Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge Cortes, MD, Moshe Talpaz, MD, Richard M. Stone, MD, Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 97.
https://doi.org/10.1182/blood.V112.11.97.97
Published: 2008